Clinical Trial

RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1/2, dose-escalation and expansion study investigating the safety, pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced solid tumors progressing from previous lines of therapy.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-09-10; most recent amendment 2024-12-12.
Status change: Recruiting → Active, Not Recruiting 2024-10-24
Trial Details
NCT Number NCT05052255
Lead Sponsor Ryvu Therapeutics SA
Conditions Advanced Solid Tumor
Enrollment 120 participants
Start Date 2021-08-13
Primary Completion 2025-05 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2024-12-17